MDACC Study No:2011-0547 ( NCT No: NCT01451437)
Title:A Phase 1 Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination with Chemotherapy in Subjects with Refractory, or Recurrent Acute Myelogenous Leukemia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:MK-8242
Study Status:Open
Study Description:The goal of this genetic sub-study is to look at how people's genes may
influence if and how well the study drug may affect the disease. This is
called pharmacogenetic (PGt) testing.

The genetic research in this sub-study involves looking at samples of DNA (the
genetic material of cells) and bone marrow samples.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I
Treatment Agents:MK-8242
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-5630
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults